Real Clinical Evidence: What UK Trials Actually Show
Understanding Wegovy vs Mounjaro Side Effects in UK Clinical Practice
When comparing Wegovy vs Mounjaro side effects, both prescription-only medicines share similar gastrointestinal profiles due to their action on gut hormones. The most commonly reported side effects include nausea, vomiting, diarrhoea, and constipation, typically occurring during dose escalation phases. However, Wegovy's single GLP-1 mechanism may cause nausea in approximately 20% of patients during initial weeks, whilst Mounjaro's dual GIP/GLP-1 action shows slightly different timing and intensity patterns. Understanding these Wegovy vs Mounjaro side effects helps patients prepare for their weight management journey and work with prescribers to minimise discomfort.
The severity of Wegovy vs Mounjaro side effects often depends on individual tolerance and proper dose escalation protocols. Most gastrointestinal symptoms improve significantly after 4-8 weeks as the body adapts to treatment. Both medications require careful monitoring during the first three months, with our clinical team providing ongoing support throughout your treatment. Serious side effects remain rare but require immediate medical attention, including signs of pancreatitis, severe dehydration, or allergic reactions.
UK Weight Loss Results: Pricing and Clinical Value Comparison
EverydayMeds offers transparent pricing for both treatments, with Wegovy starting at £79.99 for the 0.25mg starter dose using code FIRST40. Our bundle options provide convenient multi-month supplies, including the Intro Trio (0.25mg, 0.5mg, and 1mg) for £299.99 or the Ultimate Stability Trio (three 2.4mg maintenance pens) for £649.99. Returning customers benefit from code DOSE25 applied at checkout, ensuring continued access to these evidence-based treatments. Both medications represent significant investment in long-term health outcomes, with clinical trials demonstrating sustained weight management when used alongside lifestyle modifications.
The value proposition extends beyond initial costs when considering the comprehensive support provided through our GPhC-registered pharmacy (#9012878). Each prescription includes detailed administration guidance, side effect management protocols, and access to our clinical team for ongoing questions. Cold-chain delivery ensures medication integrity, whilst our 24-hour express prescriber review service minimises delays in starting treatment. Understanding Wegovy vs Mounjaro side effects and costs helps patients make informed decisions about their weight management investment.
STEP Trial Evidence: Wegovy's Proven UK Weight Loss Results
Clinical evidence from the landmark STEP trials provides robust data on Wegovy's effectiveness in UK populations. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 3 trial demonstrated even greater results with intensive behavioural therapy, reaching approximately 16% average weight loss.
Long-term data from STEP 5 showed sustained weight loss of approximately 15.2% at two years, whilst the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events. When examining Wegovy vs Mounjaro side effects alongside efficacy data, both treatments show compelling evidence, though direct head-to-head comparisons aren't available due to different trial designs and populations studied.
How Wegovy Works: GLP-1 Mechanism and Appetite Control
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural hormone that signals fullness after meals. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, leading to smaller portion sizes and reduced food cravings. The once-weekly injection provides consistent hormone levels, supporting sustained appetite reduction throughout the week. Unlike Mounjaro's dual GIP/GLP-1 approach, Wegovy's single-target mechanism offers predictable effects with well-established safety data. Understanding how these different mechanisms contribute to Wegovy vs Mounjaro side effects helps patients anticipate their treatment experience and work effectively with healthcare providers.
Streamlined Ordering Process: From Assessment to Delivery
Starting treatment through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, covering medical history, current medications, and weight management goals. Our qualified prescribers review applications within three working days (or 24 hours with express service), ensuring appropriate candidacy for either treatment option. Once approved, medications ship via next-day delivery using temperature-controlled cold-chain logistics to maintain efficacy. The process includes detailed injection technique guidance and side effect monitoring protocols. Our ongoing support helps patients navigate any concerns about Wegovy vs Mounjaro side effects whilst maintaining treatment adherence and safety.
Storage Requirements and Practical Considerations
Wegovy offers significant storage advantages when comparing practical aspects of treatment, remaining stable for six weeks at room temperature below 30°C once removed from refrigeration. This flexibility supports travel and reduces anxiety about temporary storage issues, unlike some alternatives with shorter room-temperature stability. The FlexTouch pen system provides accurate dosing with simple injection technique, whilst the mandatory dose escalation protocol (0.25mg to 2.4mg over 16 weeks) minimises side effects. Proper storage maintains medication potency and reduces the risk of injection-site reactions. Understanding these practical elements alongside Wegovy vs Mounjaro side effects ensures successful long-term treatment outcomes and patient confidence in their weight management approach.
UK-Specific Considerations: NICE Guidelines and NHS Context
The National Institute for Health and Care Excellence (NICE) has evaluated both treatments under technology appraisal guidance, recommending Wegovy with specialist weight management support for eligible patients. This approval reflects robust clinical evidence and cost-effectiveness analysis specific to UK healthcare contexts. Understanding Wegovy vs Mounjaro side effects becomes particularly relevant when considering NHS pathway integration and private prescription options. Many patients begin treatment privately to avoid waiting lists whilst maintaining continuity with their NHS care team.
UK prescribing patterns show increasing adoption of both treatments, with clinical experience helping refine patient selection criteria and side effect management protocols. The MHRA's black triangle monitoring ensures ongoing safety surveillance, with healthcare professionals reporting any unexpected effects through the Yellow Card scheme. This comprehensive oversight provides additional confidence when comparing Wegovy vs Mounjaro side effects and choosing appropriate treatment options.
Making Your Choice: Expert Guidance and Next Steps
Both Wegovy and Mounjaro are available from EverydayMeds, with our prescribing team helping determine which option best suits your medical profile and weight loss objectives. Factors influencing choice include previous medication responses, existing health conditions, lifestyle requirements, and individual preferences regarding Wegovy vs Mounjaro side effects. Our clinical assessment process evaluates these factors comprehensively, ensuring appropriate treatment selection and ongoing monitoring. Start your assessment today using code FIRST40 for new customers, with express review available for those seeking rapid treatment initiation. Visit https://everydaymeds.co.uk/collections/wegovy to begin your evidence-based weight management journey with expert clinical support throughout your treatment experience.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
